6FX0
Structure-based design of Trifarotene (CD5789), a potent and selective RAR gamma agonist for the treatment of acne
Summary for 6FX0
Entry DOI | 10.2210/pdb6fx0/pdb |
Descriptor | Retinoic acid receptor gamma, 6-[3-(1-adamantyl)-4-oxidanyl-phenyl]naphthalene-2-carboxylic acid, TETRAETHYLENE GLYCOL, ... (4 entities in total) |
Functional Keywords | retinoic ligand complex, drug design, selectivity, agonist, signaling protein |
Biological source | Homo sapiens (Human) |
Cellular location | Nucleus: P13631 |
Total number of polymer chains | 1 |
Total formula weight | 50997.57 |
Authors | Chantalat, L.,Thoreau, E. (deposition date: 2018-03-08, release date: 2018-05-23, Last modification date: 2024-05-08) |
Primary citation | Thoreau, E.,Arlabosse, J.M.,Bouix-Peter, C.,Chambon, S.,Chantalat, L.,Daver, S.,Dumais, L.,Duvert, G.,Feret, A.,Ouvry, G.,Pascau, J.,Raffin, C.,Rodeville, N.,Soulet, C.,Tabet, S.,Talano, S.,Portal, T. Structure-based design of Trifarotene (CD5789), a potent and selective RAR gamma agonist for the treatment of acne. Bioorg. Med. Chem. Lett., 28:1736-1741, 2018 Cited by PubMed: 29706423DOI: 10.1016/j.bmcl.2018.04.036 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.9 Å) |
Structure validation
Download full validation report